Voting results of the Fiscal 2025 Annual General Meeting of Pluxee Amsterdam-Schiphol, December 17, 2025 // Pluxee N.V. (“Pluxee”) held today its Annual General Meeting of Shareholders, in Amsterdam-Schipol, chaired by Didier Michaud-Daniel, Executive Chair of Pluxee’s Board of Directors. All resolutions on the agenda were approved by the shareholders. This included the adoption of the financial statements for the fiscal year which ended on August 31, 2025 (“Fiscal 2025”), and of the dividend distribution ...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), an AI-driven safety and robotics solutions company, today announced that it has established a non-binding supplier framework to support the deployment of its solutions for a government agency in Japan. The framework outlines a collaborative path to introduce AMC’s quadruped robotics platform and expand its capabilities for the Japanese market. This includes joint work on AI-powered security ...

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, providing rapid and actionable insights from terabytes of proprietary data [2] - The platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, allowing for advanced drug discovery beyond traditional methods [2] Clinical Programs - The lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-2316, a second clinical stage asset, is a potent WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data via a conference call and webcast in January 2026, including interim data from ongoing trials and new preclinical candidates [1][6]

Core Viewpoint - YXT.com Group Holding Limited has filed a shelf registration statement with the SEC to offer and sell up to $100 million of its securities, providing the company with financial flexibility for future capital needs [2][3]. Company Overview - YXT.com is a technology company focused on AI-enabled enterprise productivity solutions, aiming to empower organizational development through technology [6]. - The company has a mission to enhance enterprise productivity by leveraging over a decade of experience in tech-enabled talent learning and development [6]. - YXT.com has received recognition from numerous Global and China Fortune 500 companies since its inception [6]. Registration Statement Details - The registration statement allows YXT.com to offer various types of securities, including Class A ordinary shares, preferred shares, warrants, subscription rights, and units [2]. - The company is not obligated to sell securities under the registration statement, and the terms of any offerings will be determined based on market conditions at the time of the offering [2][3]. - The registration statement has been filed but is not yet effective, meaning no securities can be sold or offered until it is declared effective by the SEC [3].

Core Insights - ASP Isotopes has received all necessary regulatory approvals for the acquisition of Renergen, allowing the scheme to proceed [1][2] - The acquisition aims to create a global leader in the production of critical materials, including helium and isotopically enriched gases, with significant synergies expected from 2026 [3][4] - Positive operational progress has been reported at Renergen's Virginia Gas Project, with a production update anticipated by the end of January 2026 [4] Company Overview - ASP Isotopes is focused on developing technology for isotope production, utilizing proprietary Aerodynamic Separation Process technology [5] - The company plans to enrich isotopes for various sectors, including healthcare, technology, and nuclear energy [5][6] - There is a growing demand for specific isotopes for applications in quantum computing and green energy [6] Acquisition Details - Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each share held, as part of the acquisition scheme [1] - The implementation of the scheme will commence upon receipt of a compliance certificate from the South African Takeover Regulation Panel, expected around December 18, 2025 [2] - The merger is expected to create a vertically and horizontally integrated supply chain with substantial geographic and customer overlap [3]

Core Insights - SCHMID Group N.V. has secured a two-tranche term loan facility of up to €10 million to strengthen its financial structure and working capital [1][2] - The first tranche of €2.5 million is expected to be drawn on December 18, 2025, with the second tranche anticipated in early 2026 [2] - The company appointed Arthur Schuetz as the new Chief Financial Officer, effective January 1, 2026, bringing over 20 years of investment banking experience [3][4] Financial Structure - The term loan includes an optional equity conversion right at a fixed share price of USD 2.15 per share [1] - A related party loan raised an additional €200,000, involving the company's Chairman, Board members, and external investors [1] - The financing aims to convert strong order intake into revenues and optimize the company's capital structure for future opportunities [2] Leadership Changes - Arthur Schuetz will replace Julia Natterer as CFO, who will focus on daily operations at Gebr. Schmid GmbH [3] - Schuetz's background includes leading equity and debt capital fundraisings and managing complex cross-border M&A transactions [3][4] - The board expresses confidence in Schuetz's ability to enhance the company's financial strategy and stakeholder value [4] Company Overview - SCHMID Group is a global leader in high-tech electronics, photovoltaics, glass, and energy systems, headquartered in Freudenstadt, Germany [7] - The company employs over 800 staff and operates technology centers and manufacturing sites in Germany and China [7] - It focuses on customized equipment and process solutions, ensuring high technology levels and sustainability in production processes [7]

Core Viewpoint - Kyverna Therapeutics, Inc. has announced a public offering of 13,333,333 shares at a price of $7.50 per share, aiming to raise approximately $100 million before expenses [1][2]. Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead candidate being miv-cel, an autologous CD19-targeting CAR T-cell therapy [5][6]. Offering Details - The public offering is expected to close on or about December 18, 2025, pending customary closing conditions [1]. - The underwriters have a 30-day option to purchase up to 1,999,999 additional shares at the public offering price [1]. Management and Underwriters - J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities are acting as joint book-running managers for the offering [2].

ATHENS, Greece, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company providing worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, provides a commercial update on earnings and vessel employment. Vessel Employment Updates In December 2025, we extended the time charter of the M/V Alfa with an international commodity trading conglomerate for an indefinite period, expiring upon three month ...

Core Insights - Tenax Therapeutics announced that the Blinded Sample Size Re-estimation (BSSR) of the LEVEL trial shows it is adequately powered to detect a 25-meter change in the 6-minute walk distance (6MWD), confirming that the target enrollment remains unchanged and is expected to complete in the first half of 2026 [1][2][3] Group 1: LEVEL Study Details - LEVEL is a Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) for patients with pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) in the U.S. and Canada [2] - The BSSR results indicated that the observed change in 6MWD from the first 150 randomized patients was less than the assumed 55 meters [2] - The company expects to share topline data in the second half of 2026 and remains confident in executing its Phase 3 development plan for TNX-103 [3] Group 2: LEVEL-2 Study Initiation - Tenax has initiated LEVEL-2, a global Phase 3 study of TNX-103, aiming to enroll approximately 540 PH-HFpEF patients with a 2:1 randomization to receive TNX-103 or placebo [3][4] - The primary endpoint for LEVEL-2 is the change in 6MWD at Week 26, with secondary endpoints including changes in Kansas City Cardiomyopathy Questionnaire (KCCQ) and New York Heart Association (NYHA) Functional Class [3] Group 3: Global Study Sites and Safety Observations - Over 100 sites across 15 countries have been selected for participation in LEVEL-2, with a rigorous process implemented to ensure consistency in patient hemodynamic assessments [4] - The LEVEL-2 study includes a 6-month blinded safety observation following the 26-week efficacy assessment to provide a robust safety database for regulatory review [4] Group 4: Levosimendan Overview - Levosimendan is a first-in-class K-ATP channel activator/calcium sensitizer being evaluated for treating PH-HFpEF, with market authorization in 60 countries for intravenous use in acutely decompensated heart failure [5] - The Phase 2 HELP study demonstrated the potential of both intravenous (TNX-101) and oral (TNX-103) formulations to improve exercise capacity and quality of life in patients with PH-HFpEF [5] Group 5: Company Background - Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on novel cardiopulmonary therapies, holding global rights to develop and commercialize levosimendan for PH-HFpEF, which currently lacks approved treatments [7]

Core Insights - Creative Medical Technology Holdings, Inc. has successfully completed patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201, a non-opioid therapy for chronic lower back pain [1][3][4] - The completion of enrollment marks a significant milestone, transitioning the trial into follow-up and data analysis phases, with expectations of generating meaningful clinical data [3][4][8] - CELZ-201 is positioned to address a large, underserved market, with chronic lower back pain affecting over 16 million Americans and representing a multi-billion-dollar market [3][6] Company Developments - The ADAPT trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and preliminary efficacy of CELZ-201 [5] - The trial has received a positive safety review from an independent Data Safety Monitoring Board, confirming a favorable safety profile for CELZ-201 [2][5] - The company’s StemSpine® intellectual property portfolio enhances its strategic position as it moves toward later-stage clinical development and potential commercialization [7] Future Outlook - Following enrollment completion, the company plans to continue scheduled DSMB reviews, advance toward topline safety and efficacy readouts, and evaluate strategic pathways for late-stage development and commercialization [9][10] - Management emphasizes a results-driven phase, focusing on executing flawlessly and generating compelling data to unlock the full value of CELZ-201 for patients and shareholders [10]